Merrill maintains Biogen at neutral

Biogen Idec Inc. was maintained by Merrill Lynch analyst Eric Ende at neutral. The Food and Drug Administration extended its review of the Tysabri sBLA for multiple sclerosis by 90 days, primarily to review the risk management plan. Merrill expects Tysabri's re-entry to the market in the third-quarter 2006. Shares of the Cambridge, Mass., pharmaceutical company were down 21 cents, or 0.43%, at $48.10 on volume of 4,634,459 shares versus the three-month running average of 3,486,690 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.